Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Uploaded on Feb 17, 2012
Dr. Tevi Troy, senior fellow at the Hudson Institute and former deputy secretary of the US Department of Health and Human Services, says that it can be challenging for pharmaceutical companies to respond to comparative effectiveness research (CER) findings. He says that the Food and Drug Administration (FDA) should provide clear guidance as to how and when companies will be able to respond. Dr. Troy spoke during a Feb. 2012 meeting, "Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making."